Get started
Zenas BioPharma, Inc.Zenas BioPharma, Inc.Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFsBonds
Full chart
Full chart

Compare with Zenas BioPharma, Inc.



Key stats


Market capitalization
‪2.03 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−9.61 USD
Net income (FY)
‪−377.74 M‬ USD
Revenue (FY)
‪10.00 M‬ USD
Shares float
‪33.11 M‬
Beta (1Y)
−0.30

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
167
Change (1Y)
+37+28.46%
Revenue / Employee (1Y)
‪59.88 K‬ USD
Net income / Employee (1Y)
‪−2.26 M‬ USD

Company info


Sector
Health Technology
Industry
Biotechnology
CEO
Leon Oliver Moulder
Website
zenasbio.com
Headquarters
Waltham
Founded
2019
IPO date
Sep 13, 2024
ISIN
US98937L1052
CUSIP
98937L105
FIGI
BBG01J1MG9D6
Identifiers
ISIN US98937L1052
CFI code
ESVUFR
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


— YTM
Maturity dateApr 1, 2032
Coupon2.50% (Fixed)

See all ZBIO bonds 

ETFs holding the stock


XBI
State Street SPDR S&P Biotech ETF
Weight0.41%
Market value‪42.57 M‬
IWM
iShares Russell 2000 Index Fund
Weight0.03%
Market value‪22.76 M‬
IWO
iShares Russell 2000 Growth Fund
Weight0.06%
Market value‪8.33 M‬
IBB
iShares Biotechnology ETF
Weight0.07%
Market value‪7.55 M‬
SCHA
Schwab U.S. Small-Cap ETF
Weight0.03%
Market value‪5.67 M‬
VTWO
Vanguard Russell 2000 ETF
Weight0.03%
Market value‪5.02 M‬
IWC
iShares Microcap ETF
Weight0.21%
Market value‪3.01 M‬
SBIO
ALPS Medical Breakthroughs ETF
Weight1.16%
Market value‪2.71 M‬
VHT
Vanguard Health Care ETF
Weight0.01%
Market value‪2.53 M‬
FFSM
Fidelity Fundamental Small-Mid Cap ETF
Weight0.14%
Market value‪2.08 M‬
ZPRR
State Street SPDR RUSSELL 2000 U.S. SMALL CAP UCITS ETF Accum Ptg USD
Weight0.03%
Market value‪1.75 M‬

Explore more ETFs 

Frequently asked questions


The current price of ZBIO is 31.19 USD — it has increased by 0.06% in the past 24 hours. Watch Zenas BioPharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Zenas BioPharma, Inc. stocks are traded under the ticker ZBIO.
ZBIO stock has fallen by −4.72% compared to the previous week, the month change is a −2.90% fall, over the last year Zenas BioPharma, Inc. has showed a 54.87% increase.
We've gathered analysts' opinions on Zenas BioPharma, Inc. future price: according to them, ZBIO price has a max estimate of 59.00 USD and a min estimate of 32.00 USD. Watch ZBIO chart and read a more detailed Zenas BioPharma, Inc. stock forecast: see what analysts think of Zenas BioPharma, Inc. and suggest that you do with its stocks.
ZBIO reached its all-time high on Dec 24, 2025 with the price of 44.60 USD, and its all-time low was 5.83 USD and was reached on Jan 28, 2025. View more price dynamics on ZBIO chart.
See other stocks reaching their highest and lowest prices.
ZBIO stock is 4.04% volatile and has beta coefficient of −0.30. Track Zenas BioPharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Zenas BioPharma, Inc. there?
Today Zenas BioPharma, Inc. has the market capitalization of ‪2.03 B‬, it has increased by 1.56% over the last week.
Yes, you can track Zenas BioPharma, Inc. financials in yearly and quarterly reports right on TradingView.
Zenas BioPharma, Inc. is going to release the next earnings report on Nov 18, 2026. Keep track of upcoming events with our Earnings Calendar.
ZBIO earnings for the last quarter are −1.77 USD per share, whereas the estimation was −1.12 USD resulting in a −57.71% surprise. The estimated earnings for the next quarter are −1.22 USD per share. See more details about Zenas BioPharma, Inc. earnings.
Zenas BioPharma, Inc. revenue for the last quarter amounts to ‪1.00 M‬ USD, despite the estimated figure of ‪15.00 M‬ USD. In the next quarter, revenue is expected to reach 0.00 USD.
ZBIO net income for the last quarter is ‪−111.46 M‬ USD, while the quarter before that showed ‪−80.99 M‬ USD of net income which accounts for 0.00% change. Track more Zenas BioPharma, Inc. financial stats to get the full picture.
No, ZBIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 14, 2026, the company has 167 employees. See our rating of the largest employees — is Zenas BioPharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Zenas BioPharma, Inc. EBITDA is ‪−273.87 M‬ USD, and current EBITDA margin is ‪−2.11 K‬%. See more stats in Zenas BioPharma, Inc. financial statements.
Like other stocks, ZBIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Zenas BioPharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Zenas BioPharma, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Zenas BioPharma, Inc. stock shows the buy signal. See more of Zenas BioPharma, Inc. technicals for a more comprehensive analysis.